ES2051152B1 - PROCEDURE OF SYSTESIS OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES ANTI-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS. - Google Patents

PROCEDURE OF SYSTESIS OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES ANTI-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS.

Info

Publication number
ES2051152B1
ES2051152B1 ES09101525A ES9101525A ES2051152B1 ES 2051152 B1 ES2051152 B1 ES 2051152B1 ES 09101525 A ES09101525 A ES 09101525A ES 9101525 A ES9101525 A ES 9101525A ES 2051152 B1 ES2051152 B1 ES 2051152B1
Authority
ES
Spain
Prior art keywords
rsi2
rsi1
amino acids
peptides
aasi15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09101525A
Other languages
Spanish (es)
Other versions
ES2051152A1 (en
Inventor
Lasarte Carmen Berasain
Marquez Marta Garcia-Granero
Jose Ignacio Riezu-Boj
Valtuena Jesus Prieto
Cuesta Francisco Borras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES9301361A priority Critical patent/ES2069476B1/en
Publication of ES2051152A1 publication Critical patent/ES2051152A1/en
Application granted granted Critical
Publication of ES2051152B1 publication Critical patent/ES2051152B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCEDIMIENTO DE SINTESIS DE PEPTIDOS CON CAPACIDAD DE DETECTAR ANTICUERPOSANTI-VIRUS DE LA HEPATITIS C (VHC) EN SUERO DE INDIVIDUOS INFECTADOS, TENIENDO DICHOS PEPTIDOS LA FORMULA GENERAL SIGUIENTE: RSI1-SC-AASI1-SC-AASI2-SC-AASI3-SC-AASI4-SC-AASI5-SC-AASI6-SC-AASI7-SC-AASI8-SC-AASI9-SC-AASI10-SC-AASI11-SC-AASI12-SC-AASI13-SC-AASI14-SC-AASI15-SC- RSI2-SC EN LA QUE RSI1-SC REPRESENTA H, RSI2-SC REPRESENTA OH, O BIEN RSI1-SC Y RSI2-SC REPRESENTAN CADENAS POLIPEPTIDICAS IGUALES O DIFERENTES QUE CONTIENEN ENTRE DOS O DIEZ AMINOACIDOS DE TAL FORMA QUE CUANDO RSI1-SC = H Y RSI2-SC = OH ENTONCES LA FORMULAREPRESENTA UN PENTADECAPEPTIDO EN QUE LOS AMINOACIDOS N-TERMINAL Y C-TERMINAL SON RESPECTIVAMENTE AASI1-SC Y AASI15-SC; AASI4-SC REPRESENTA SER O ARG; AASI5-SC REPRESENTA ARG, PRO O LYS; AASI6-SC REPRESENTA GLY, GLN O THR; AASI7-SC REPRESENTA ASN, ASP O LYS; AASI10-SC REPRESENTA SER, PHE O THR; AASI11-SC REPRESENTA PRO O ASN; AASI12-SC REPRESENTA THR, GLY O ARG; Y AASI1-SC, AASI2-SC, AASI3-SC, AASI8-SC, AASI13-SC, AASI14-SC, Y AASI15-SC REPRESENTA CADA UNO A ALGUNO DE LOS 20 POSIBLES AMINOACIDOS NATURALES, CARACTERIZADO POR LAS OPERACIONES SIGUIENTES: (A) FUNCIONALIZACION DE LA RESINA, (B) UNION DEL PRIMER AMINOACIDO A LA RESINA FUNCIONALIZADA, (C) ENSAMBLAMIENTO DE LOS RESTANTES AMINOACIDOS, (D) ESCISION DEL PEPTIDO DE LA RESINA, Y (E) PURIFICACION DEL PEPTIDO.SYNTHESIS PROCEDURE OF PEPTIDES WITH THE CAPACITY TO DETECT ANTIBODY-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF INFECTED INDIVIDUALS, HAVING SUCH PEPTIDES THE GENERAL FORMULA FOLLOWING: RSI1-SC-AASI1-SC-A-SC-A-A-SC-A-A1 -SC-AASI5-SC-AASI6-SC-AASI7-SC-AASI8-SC-AASI9-SC-AASI10-SC-AASI11-SC-AASI12-SC-AASI13-SC-AASI14-SC-AASI15-SC- RSI2-SC IN WHICH RSI1-SC REPRESENTS H, RSI2-SC REPRESENTS OH, OR RSI1-SC AND RSI2-SC REPRESENT EQUAL OR DIFFERENT POLYPEPTIDE CHAINS CONTAINING BETWEEN TWO OR TEN AMINO ACIDS, WHEN WHEN RSI1-SC = HY RSI2-SC = OH THEN THE FORMULARE PRESENTS A PEPADEPEPTIFIED IN WHICH THE N-TERMINAL AND C-TERMINAL AMINO ACIDS ARE RESPECTIVELY AASI1-SC AND AASI15-SC; AASI4-SC REPRESENTS SER OR ARG; AASI5-SC REPRESENTS ARG, PRO OR LYS; AASI6-SC REPRESENTS GLY, GLN OR THR; AASI7-SC REPRESENTS ASN, ASP OR LYS; AASI10-SC REPRESENTS SER, PHE OR THR; AASI11-SC REPRESENTS PRO OR ASN; AASI12-SC REPRESENTS THR, GLY OR ARG; AND AASI1-SC, AASI2-SC, AASI3-SC, AASI8-SC, AASI13-SC, AASI14-SC, AND AASI15-SC REPRESENT EACH ONE OF THE 20 POSSIBLE NATURAL AMINO ACIDS, CHARACTERIZED BY THE FOLLOWING OPERATIONS: (A) FUNCTIONALIZATION OF THE RESIN, (B) UNION OF THE FIRST AMINO ACID TO THE FUNCTIONALIZED RESIN, (C) ASSEMBLY OF THE REMAINING AMINO ACIDS, (D) SPLITTING OF THE RESIN PEPTIDE, AND (E) PURIFICATION OF THE PEPTIDE.

ES09101525A 1991-03-20 1991-06-28 PROCEDURE OF SYSTESIS OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES ANTI-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS. Expired - Lifetime ES2051152B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9301361A ES2069476B1 (en) 1991-06-28 1993-06-18 SYNTHESIS PROCEDURE OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919105871A GB9105871D0 (en) 1991-03-20 1991-03-20 Synthetic peptides
PCT/ES1993/000051 WO1995000545A1 (en) 1991-03-20 1993-06-18 Synthetic peptides for the detection of antibodies against the virus of hepatitis c in the serum of infected persons

Publications (2)

Publication Number Publication Date
ES2051152A1 ES2051152A1 (en) 1994-06-01
ES2051152B1 true ES2051152B1 (en) 1994-12-16

Family

ID=10691867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09101525A Expired - Lifetime ES2051152B1 (en) 1991-03-20 1991-06-28 PROCEDURE OF SYSTESIS OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES ANTI-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS.

Country Status (4)

Country Link
AU (1) AU4327793A (en)
ES (1) ES2051152B1 (en)
GB (1) GB9105871D0 (en)
WO (1) WO1995000545A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670310A (en) * 1994-07-29 1997-09-23 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for differential diagnosis of acute and chronic hepatitis c virus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484787B1 (en) * 1990-11-03 2001-10-10 Dade Behring Marburg GmbH HCV-specific peptides, process for obtaining them and their use
GB9028097D0 (en) * 1990-12-27 1991-02-13 Inst Technologico Y Cientifico New synthetic peptides active as immunomodulators
EP0571554A1 (en) * 1991-01-14 1993-12-01 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
AU2683792A (en) * 1991-09-16 1993-04-27 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays

Also Published As

Publication number Publication date
AU4327793A (en) 1995-01-17
ES2051152A1 (en) 1994-06-01
WO1995000545A1 (en) 1995-01-05
GB9105871D0 (en) 1991-05-08

Similar Documents

Publication Publication Date Title
Carlsen et al. Human chorionic gonadotropin: linear amino acid sequence of the β subunit
Blombäck et al. Primary Structure of Human Fibrinogen and Fibrin: II. STRUCTURAL STUDIES ON NH2-TERMINAL PART OF γ CHAIN
Wilkinson The amino acid sequence of troponin C from chicken skeletal muscle
MX9606536A (en) N-terminally extended proteins expressed in yeast.
NO950668L (en) Peptides derived from a retrovirus from the HIV group and uses thereof
NO972930L (en) Fibronectin-adhesion inhibitors
KR850003417A (en) Method of producing polypeptide
ES2063350T3 (en) NEW PROTEINS WITH AN INHIBITING EFFECT OF TNF AND ITS PRODUCTION.
KR850002283A (en) Method for preparing homologous immune interferon fragment
Han et al. The covalent structure of beef heart myoglobin
KR880009125A (en) Pancreatic secretive trypsin inhibitors and variants thereof, methods thereof, expression vectors and recombinant hosts and pharmaceutical uses thereof produced by recombinant hosts
BR9306272A (en) Peptide and pharmaceutical composition
ES2052791T3 (en) NEW PEPTIDES SIGNAL ABLE TO WORK IN YEAST, AND SECRETING EXPRESSION OF HETEROLOGICAL PROTEINS THAT USE THEM.
ATE154361T1 (en) BINDING PEPTIDES
DE69827262D1 (en) PENAEIDINE: ANTIMICROBIAL PEPTIDES FROM CARBURATORS
Adlersberg et al. Repetitive hinge region sequences in human IgG3: isolation of an 11,000-dalton fragment.
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides
Timpl et al. Cyanogen bromide cleavage of bovine fibrinogen. Identification of a dimeric N-terminal peptide and two other disulfide containing fragments
ES2051152B1 (en) PROCEDURE OF SYSTESIS OF PEPTIDES WITH THE CAPACITY TO DETECT ANTI-BODIES ANTI-VIRUSES OF HEPATITIS C (HCV) IN SERUM OF AFFECTED INDIVIDUALS.
KR860006484A (en) Method for preparing protein or glycoprotein
KR930000684A (en) Cloned Glutamate Decarboxylase
Meloun et al. Amino acid sequence of 37 residues at the carboxyl—terminal end of human plasma albumin
KR850002285A (en) Method of producing immune interferon
Inouye et al. The Amino Acid Sequence of T4 Phage Lysozyme: II. CHYMOTRYPTIC DIGESTION
KR890701628A (en) Preparation of Protein (Sex) Sweeteners